280 related articles for article (PubMed ID: 22086206)
21. Multiple myeloma as a model for the role of bone marrow niches in the control of angiogenesis.
Ribatti D; Nico B; Vacca A
Int Rev Cell Mol Biol; 2015; 314():259-82. PubMed ID: 25619720
[TBL] [Abstract][Full Text] [Related]
22. Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.
Basile A; Moschetta M; Ditonno P; Ria R; Marech I; De Luisi A; Berardi S; Frassanito MA; Angelucci E; Derudas D; Specchia G; Curci P; Pavone V; Rossini B; Ribatti D; Bottazzi B; Mantovani A; Presta M; Dammacco F; Vacca A
J Pathol; 2013 Jan; 229(1):87-98. PubMed ID: 22847671
[TBL] [Abstract][Full Text] [Related]
23. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
[TBL] [Abstract][Full Text] [Related]
24. Angiopoietin-1 and myeloma-induced angiogenesis.
Giuliani N; Colla S; Morandi F; Rizzoli V
Leuk Lymphoma; 2005 Jan; 46(1):29-33. PubMed ID: 15621778
[TBL] [Abstract][Full Text] [Related]
25. Antiangiogenic therapeutic approaches in multiple myeloma.
Ribatti D; Mangialardi G; Vacca A
Curr Cancer Drug Targets; 2012 Sep; 12(7):768-75. PubMed ID: 22780844
[TBL] [Abstract][Full Text] [Related]
26. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF.
Sun CY; She XM; Qin Y; Chu ZB; Chen L; Ai LS; Zhang L; Hu Y
Carcinogenesis; 2013 Feb; 34(2):426-35. PubMed ID: 23104180
[TBL] [Abstract][Full Text] [Related]
27. Bone marrow angiogenesis in multiple myeloma.
Vacca A; Ribatti D
Leukemia; 2006 Feb; 20(2):193-9. PubMed ID: 16357836
[TBL] [Abstract][Full Text] [Related]
28. Integrin alpha4beta1 involvement in stromal cell-derived factor-1alpha-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion.
Parmo-Cabañas M; Bartolomé RA; Wright N; Hidalgo A; Drager AM; Teixidó J
Exp Cell Res; 2004 Apr; 294(2):571-80. PubMed ID: 15023543
[TBL] [Abstract][Full Text] [Related]
29. HIF-2α-ILK Is Involved in Mesenchymal Stromal Cell Angiogenesis in Multiple Myeloma Under Hypoxic Conditions.
Zhang X; Xu Y; Liu H; Zhao P; Chen Y; Yue Z; Zhang Z; Wang X
Technol Cancer Res Treat; 2018 Jan; 17():1533033818764473. PubMed ID: 29656700
[TBL] [Abstract][Full Text] [Related]
30. Induction of angiogenesis by normal and malignant plasma cells.
Hose D; Moreaux J; Meissner T; Seckinger A; Goldschmidt H; Benner A; Mahtouk K; Hillengass J; Rème T; De Vos J; Hundemer M; Condomines M; Bertsch U; Rossi JF; Jauch A; Klein B; Möhler T
Blood; 2009 Jul; 114(1):128-43. PubMed ID: 19299335
[TBL] [Abstract][Full Text] [Related]
31. Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression.
Wang J; De Veirman K; Faict S; Frassanito MA; Ribatti D; Vacca A; Menu E
J Pathol; 2016 Jun; 239(2):162-73. PubMed ID: 26956697
[TBL] [Abstract][Full Text] [Related]
32. Cytokine network: new targeted therapy for pancreatic cancer.
Matsuo Y; Takeyama H; Guha S
Curr Pharm Des; 2012; 18(17):2416-9. PubMed ID: 22372505
[TBL] [Abstract][Full Text] [Related]
33. Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression.
Kline M; Donovan K; Wellik L; Lust C; Jin W; Moon-Tasson L; Xiong Y; Witzig TE; Kumar S; Rajkumar SV; Lust JA
Leuk Res; 2007 May; 31(5):591-8. PubMed ID: 16879867
[TBL] [Abstract][Full Text] [Related]
34. Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion.
De Veirman K; De Beule N; Maes K; Menu E; De Bruyne E; De Raeve H; Fostier K; Moreaux J; Kassambara A; Hose D; Heusschen R; Eriksson H; Vanderkerken K; Van Valckenborgh E
Cancer Immunol Res; 2017 Oct; 5(10):839-846. PubMed ID: 28903971
[TBL] [Abstract][Full Text] [Related]
35. Angiogenesis in multiple myeloma.
Rajkumar SV; Kyle RA
Semin Oncol; 2001 Dec; 28(6):560-4. PubMed ID: 11740809
[TBL] [Abstract][Full Text] [Related]
36. The hypoxia target adrenomedullin is aberrantly expressed in multiple myeloma and promotes angiogenesis.
Kocemba KA; van Andel H; de Haan-Kramer A; Mahtouk K; Versteeg R; Kersten MJ; Spaargaren M; Pals ST
Leukemia; 2013 Aug; 27(8):1729-37. PubMed ID: 23478664
[TBL] [Abstract][Full Text] [Related]
37. EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells.
La Rocca F; Airoldi I; Di Carlo E; Marotta P; Falco G; Simeon V; Laurenzana I; Trino S; De Luca L; Todoerti K; Villani O; Lackmann M; D'Auria F; Frassoni F; Neri A; Del Vecchio L; Musto P; Cilloni D; Caivano A
Cell Oncol (Dordr); 2017 Oct; 40(5):483-496. PubMed ID: 28721629
[TBL] [Abstract][Full Text] [Related]
38. Proteasome inhibitors and modulators of angiogenesis in multiple myeloma.
Ferrarini M; Ferrero E
Curr Med Chem; 2011; 18(34):5185-95. PubMed ID: 22087819
[TBL] [Abstract][Full Text] [Related]
39. Potential role of FLT3-ligand in the angiogenic process of multiple myeloma.
Kokonozaki M; Tsirakis G; Devetzoglou M; Kyriakaki S; Antonakis A; Vyzoukaki R; Pappa CA; Tzardi M; Alexandrakis MG
Leuk Res; 2015 Dec; 39(12):1467-72. PubMed ID: 26521986
[TBL] [Abstract][Full Text] [Related]
40. Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets.
Berardi S; Caivano A; Ria R; Nico B; Savino R; Terracciano R; De Tullio G; Ferrucci A; De Luisi A; Moschetta M; Mangialardi G; Catacchio I; Basile A; Guarini A; Zito A; Ditonno P; Musto P; Dammacco F; Ribatti D; Vacca A
Oncogene; 2012 May; 31(18):2258-69. PubMed ID: 21963844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
